JP2024530990A - 治療方法 - Google Patents

治療方法 Download PDF

Info

Publication number
JP2024530990A
JP2024530990A JP2024513439A JP2024513439A JP2024530990A JP 2024530990 A JP2024530990 A JP 2024530990A JP 2024513439 A JP2024513439 A JP 2024513439A JP 2024513439 A JP2024513439 A JP 2024513439A JP 2024530990 A JP2024530990 A JP 2024530990A
Authority
JP
Japan
Prior art keywords
seq
set forth
dna
binding protein
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530990A5 (https=
Inventor
ジェームス・エー・キャンベル
ヴァレンティーナ・ドゥブリェヴィッチ
ジェームズ・イー・ハンセン
シャオヨン・チェン
ベネデット・ジェー・カファリ
アヌパマ・シラリ
ジアンビン・ジョウ
Original Assignee
ニュークリアス・セラピューティクス・ピーティーワイ・リミテッド
イェール・ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニュークリアス・セラピューティクス・ピーティーワイ・リミテッド, イェール・ユニヴァーシティー filed Critical ニュークリアス・セラピューティクス・ピーティーワイ・リミテッド
Publication of JP2024530990A publication Critical patent/JP2024530990A/ja
Publication of JP2024530990A5 publication Critical patent/JP2024530990A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2024513439A 2021-08-30 2022-08-30 治療方法 Pending JP2024530990A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163238657P 2021-08-30 2021-08-30
US63/238,657 2021-08-30
US202263324784P 2022-03-29 2022-03-29
US63/324,784 2022-03-29
PCT/US2022/075639 WO2023034778A1 (en) 2021-08-30 2022-08-30 Method of treatment

Publications (2)

Publication Number Publication Date
JP2024530990A true JP2024530990A (ja) 2024-08-27
JP2024530990A5 JP2024530990A5 (https=) 2025-09-08

Family

ID=85411616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513439A Pending JP2024530990A (ja) 2021-08-30 2022-08-30 治療方法

Country Status (6)

Country Link
US (1) US20250188194A1 (https=)
EP (1) EP4396225A4 (https=)
JP (1) JP2024530990A (https=)
AU (1) AU2022337199A1 (https=)
CA (1) CA3230295A1 (https=)
WO (1) WO2023034778A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025129254A1 (en) * 2023-12-19 2025-06-26 Nucleus Therapeutics Pty Ltd Composition comprising a cell penetrating, anti-dna binding protein and methods of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6178785B2 (ja) * 2011-04-01 2017-08-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
EP3471777A1 (en) * 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US20210340279A1 (en) * 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
WO2021077070A1 (en) * 2019-10-18 2021-04-22 Yale University Compositions and methods for inhibition of cell-penetrating antibodies

Also Published As

Publication number Publication date
EP4396225A4 (en) 2025-07-02
WO2023034778A1 (en) 2023-03-09
US20250188194A1 (en) 2025-06-12
CA3230295A1 (en) 2023-03-09
AU2022337199A1 (en) 2024-03-21
EP4396225A1 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
AU2022201737B2 (en) Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
US11779629B2 (en) Compositions comprising cyclic peptides derived from an A-beta peptide
JP7627687B2 (ja) Ｌｉｌｒｂ２に対するシングルドメイン抗体
AU2016353552B2 (en) N-terminal epitopes in Amyloid beta and conformationally-selective antibodies thereto
AU2016353553B2 (en) Amyloid beta epitopes and antibodies thereto
JP2020188765A (ja) Ｌｏｘ１特異的結合タンパク質及びその使用
JP2021531825A (ja) 葉酸受容体アルファに特異的な抗体
US20210122818A1 (en) Humanized anti-bag3 antibodies
US20220119546A1 (en) Plectin-1 binding antibodies and uses thereof
EP2048162A1 (en) Novel monoclonal antibody and use of the same
JP2019510080A (ja) 骨疾患、障害及び／または傷害の治療方法及びそのための試薬
US20250163149A1 (en) Anti-rage antibody
US20250188194A1 (en) Method of treatment
JP5704722B2 (ja) 細胞接着阻害剤およびその用途
JP6029019B2 (ja) 細胞接着阻害剤、細胞増殖阻害剤、並びに癌の検査方法および検査用キット
US11028184B2 (en) Long-acting PCSK9-specific binding protein and application thereof
EP3647426A1 (en) Fusion protein
US8722041B2 (en) Anti-human equilibrative nucleoside transporter 1 (hENT1) antibodies and methods of use thereof
JPWO2006093337A1 (ja) 癌の予防・治療剤
CN118201958A (zh) 治疗方法
WO2024153193A1 (en) Bi-specific molecules targeting sirpa and claudin 18.2
JP2023521521A (ja) 新規α－シンヌクレイン結合抗体又はその抗原結合部分

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250829